ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) Files An 8-K Other EventsItem 8.01 Other Events.
On November 2, 2018, OncoSec Medical Incorporated (the “Company”) entered into a Sales Agreement between the Company and Cantor Fitzgerald & Co. regarding an at-the-market offering (the “Offering”) of up to $30,000,000 worth of shares of the Company’s common stock, par value $0.0001 per share. A copy of the Sales Agreement is attached hereto as Exhibit 1.1 and is incorporated by reference herein.
Alston & Bird LLP, counsel to the Company, delivered an opinion as to the validity of the shares, a copy of which is attached hereto as Exhibit 5.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are filed as part of this report:
ONCOSEC MEDICAL Inc ExhibitEX-1.1 2 ex1-1.htm OncoSec Medical Incorporated Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement November 2,…To view the full exhibit click here
About ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS)
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.